CTIS2024-511035-10-00进行中（未招募）1 期
A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa - HS0005
CB Biopharma0 个研究点目标入组 476 人开始时间: 2024年7月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 476
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Study participant has completed the Maintenance Treatment Period through Week 48 in HS0003 (NCT04242446) or HS0004 (NCT04242498), was eligible to receive bimekizumab at the time of completing the feeder study, and did not meet any withdrawal criteria of the feeder study., Study participant is considered reliable and capable of adhering to the protocol (eg, able to understand and complete questionnaires), visit schedule, and medication intake according to the judgement of the Investigator., A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: a) Not a woman of childbearing potential (WOCBP). OR b) A WOCBP who agrees to follow the contraceptive guidance during the open-label extension period and for at least 20 weeks after the final dose of investigational medicinal product (IMP)., In France and in Germany, at the time of implementation of Protocol Amendments 2.3/France and 2.4/Germany, respectively, and after the participant provides informed consent, eligible participants will continue for an additional 48-week open-label treatment period if the criteria specified in the Protocol are met. In France, Protocol Amendment 2.6/France has further extended the open-label treatment period for up to 40 additional weeks.
排除标准
- •Female study participant who is breastfeeding, pregnant, or plans to become pregnant during the study or within 20 weeks following the final dose of investigational medicinal product (IMP)., Study participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's ability to participate in this study as determined by the Investigator based on protocol required assessments. Note: For any study participant with an ongoing serious adverse event (SAE) from HS0003 (NCT04242446) or HS0004 (NCT04242498), or any current sign or symptom that may indicate a medically significant active infection (except for the common cold) or has had an infection requiring systemic antibiotics within 2 weeks of study entry or a history of serious infections in HS0003 or HS0004, the Medical Monitor must be consulted prior to the study participant's entry into HS0005, although the decision on whether to enroll the participant remains with the Investigator., Study participant has a positive or indeterminate interferon-gamma release assay (IGRA) in a feeder study, unless appropriately evaluated and treated., Study participant has ongoing or planned use of prohibited hidradenitis suppurativa (HS) or non-HS treatment., Study participant plans to participate in another study of a medicinal product or device under investigation during this study., In France and in Germany, at the time of implementation of Protocol Amendments 2.3/France and 2.4/Germany, respectively, and after the participant provides informed consent, eligible participants will continue for an additional 48-week open-label treatment period if the criteria specified in the Protocol are met. In France, Protocol Amendment 2.6/France has further extended the open-label treatment period for up to 40 additional weeks.
研究者
相似试验
进行中（未招募）
1 期
A study to test the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativaHidradenitis SuppurativaMedDRA version: 20.0Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 100000004858EUCTR2020-004179-42-NLCB Biopharma SR830
进行中（未招募）
1 期
A study to test the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativaMedDRA version: 20.0Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 100000004858Hidradenitis SuppurativaEUCTR2020-004179-42-BECB Biopharma SR658
进行中（未招募）
1 期
A study to test the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativaMedDRA version: 20.0Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersHidradenitis SuppurativaEUCTR2020-004179-42-CZCB Biopharma SR658
进行中（未招募）
1 期
A study to test the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativaHidradenitis SuppurativaMedDRA version: 20.0Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2020-004179-42-BGCB Biopharma SR658
进行中（未招募）
1 期
A study to test the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativaMedDRA version: 20.0Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 100000004858Hidradenitis SuppurativaEUCTR2020-004179-42-ITCB Biopharma SR830